Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. (Nasdaq: ARDX) is a biopharmaceutical company focused on first-in-class medicines based on inhibition of the sodium/hydrogen exchanger 3 (NHE3). Its news flow centers on the commercial performance and clinical profile of its tenapanor-based products, IBSRELA and XPHOZAH, as well as progress in its pipeline and corporate developments.
News releases from Ardelyx frequently cover product revenue trends for IBSRELA, indicated for irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH, indicated to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy when phosphate binders are inadequate or not tolerated. The company provides updates on quarterly and annual product revenue, preliminary financial results and strategic outlooks for future years.
Investors and observers can also expect coverage of clinical and real-world evidence presented at major medical meetings. Ardelyx has reported data on IBSRELA at the American College of Gastroenterology’s Annual Scientific Meeting, including patient treatment satisfaction, reductions in abdominal bloating and analyses suggesting potential reductions in healthcare resource utilization. For XPHOZAH, the company has highlighted real-world effectiveness and patient satisfaction data presented at the American Society of Nephrology’s Kidney Week, focusing on serum phosphate reduction in dialysis patients with hyperphosphatemia.
Additional Ardelyx news items include participation in healthcare and investor conferences, executive leadership changes, financing and loan amendments, and updates on the development of RDX10531, a next-generation NHE3 inhibitor. The ARDX news page on Stock Titan aggregates these announcements, allowing readers to follow product performance, clinical data disclosures and key corporate events over time.
Ardelyx (Nasdaq: ARDX) reported preliminary, unaudited 2025 product revenue of approximately $378 million with IBSRELA generating about $274 million$104 million for 2025 with ~$28 million in Q4. The company ended 2025 with $265 million in cash, cash equivalents and investments. Guidance: 2026 IBSRELA revenue is expected at $410–430 million (≥50% growth vs. 2025) and XPHOZAH at $110–120 million. Long-term outlook projects IBSRELA reaching $1 billion revenue by 2029. Corporate updates include a Phase 3 CIC trial commencing and a Notice of Allowance for a patent expiring December 6, 2041.
Ardelyx (Nasdaq: ARDX) presented real-world and clinical analyses of XPHOZAH (tenapanor) at ASN Kidney Week on November 7, 2025. Key findings: real-world initiators experienced an average serum phosphate reduction of ~1.0 mg/dL, with 45.3% of patients reducing ≥1 mg/dL and 25.1% reducing ≥2 mg/dL over a 120-day follow-up. A patient survey reported 63% felt phosphate levels were better and 69% reported improved outlook on control. Additional posters showed improved bowel movements in ESKD patients and a Japan cost-effectiveness analysis meeting a 5 million JPY willingness-to-pay threshold.
Ardelyx (Nasdaq: ARDX) management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 4:30 pm GMT / 11:30 am ET. Investors can watch a live webcast via the Events and Presentations page on the Ardelyx website. A replay will be available on the Ardelyx website for 30 days after the event.
The presentation offers a chance to hear management commentary and corporate updates directly; access is through the company website's investor events page.
Ardelyx (NASDAQ: ARDX) announced that President and CEO Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on Monday, November 10, 2025 from 11:30 a.m. to 12:00 p.m. ET.
The session will be available via a public webcast on Ardelyx's Events and Presentations webpage, and a replay will be posted on the Ardelyx website for 30 days after the event.
Ardelyx (Nasdaq: ARDX) reported Q3 2025 total revenue $110.3M and product revenue of $105.5M. IBSRELA delivered $78.2M in Q3, up 92% YoY, and guidance for full‑year 2025 IBSRELA revenue was raised to $270–275M. XPHOZAH generated $27.4M in Q3, up 9% QoQ but down versus prior year following the loss of Medicare Part D coverage effective Jan 1, 2025. Cash, cash equivalents and short‑term investments were $242.7M as of Sept 30, 2025. The company began development of RDX10531, a next‑generation NHE3 inhibitor, and expects to support an IND submission in 2026.
Q3 net loss was $1.0M; R&D was $18.1M and SG&A was $83.6M.
Ardelyx (Nasdaq: ARDX) presented real-world and clinical analyses of IBSRELA (tenapanor) at the ACG 2025 Annual Meeting (Oct 28, 2025). Key findings include high patient-reported treatment satisfaction (88%), reported improvements in constipation (95%), bloating (75%) and abdominal pain (84%), and 76% saying IBSRELA is better than prior IBS-C medications. Phase 3 T3MPO-1/2 post-hoc analyses show clinically meaningful bloating reduction as early as week one and sustained benefit. An EHR study found reductions in GI visits and patient portal messaging after tenapanor initiation among high healthcare resource users, suggesting potential to lower HCRU.
Ardelyx (Nasdaq: ARDX) announced four poster presentations supporting XPHOZAH (tenapanor) at the American Society of Nephrology Kidney Week, November 5–9, 2025 in Houston.
XPHOZAH is described as the first and only phosphate absorption inhibitor approved by the U.S. FDA to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy for patients with inadequate response or intolerance to phosphate binders; it is dosed as a single tablet twice daily.
Four posters will present real-world effectiveness, treatment satisfaction, bowel-movement benefits, and trends in etelcalcetide use and parathyroidectomy rates on November 6–7, 2025, plus an Exhibitor Spotlight on November 7, 2025 from 11:00–11:45 AM CST.
Ardelyx (Nasdaq: ARDX) will report third quarter 2025 financial results and provide a business update on Thursday, October 30, 2025 at 4:30 p.m. ET. The company will host a live conference call and simultaneous webcast accessible from the Investors section of its website at www.ardelyx.com. Domestic dial-in is (877) 346-6112 and international dial-in is (848) 280-6350. The live webcast will be archived and available for replay for 30 days after the call.
Ardelyx (Nasdaq: ARDX) announced the appointment of Sue Hohenleitner as Chief Financial Officer, effective November 4, 2025. Hohenleitner brings more than 30 years of corporate finance and operations experience and served most recently as VP and CFO of Johnson & Johnson Innovative Medicine North America, where she led financial strategies for a $36 billion commercial business. She is a CPA and CMA with a BS in Accounting and an MBA. Hohenleitner will assume the role following Ardelyx’s third quarter 2025 financial reporting; current CFO and COO Justin Renz will continue in his role through the filing of Ardelyx’s Form 10-Q.
This leadership change is positioned to support Ardelyx’s commercial expansion and long-term growth strategy while the company executes near-term financial reporting and transition steps.
Ardelyx (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines, has announced its participation in four major investor conferences in September 2025:
- Citi Biopharma Back to School Summit in Boston (Sept 3)
- Cantor Global Healthcare Conference in New York (Sept 4)
- Morgan Stanley 23rd Annual Global Healthcare Conference in New York (Sept 8)
- H.C. Wainwright 27th Annual Global Investment Conference in New York (Sept 9)
Live webcasts of the fireside chats and presentations will be available on Ardelyx's investor relations website, with replays accessible for 30 days after each event.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
